Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Role of rifampin in staphylococcal PJI | retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Role of rifampin in staphylococcal PJI | Other | the aim is to determine if the dose and the duration of rifampin influenced the prognosis |
|
| Measure | Description | Time Frame |
|---|---|---|
| description of the use of rifampicin : rate of use | the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| Measure | Description | Time Frame |
|---|---|---|
| rate of failure for treatment using rifampin | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |
| rate of adverse event with rifampin |
Not provided
Inclusion Criteria:
patients having had acute PJI (i.e. <1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)
Exclusion Criteria:
None
Not provided
Not provided
Not provided
retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tristan FERRY, Md,PhD | Hospices Civils de Lyon Hôpital de la Croix-Rousse | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Description of adverses events leading to stop the rifampicin |
| Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) |